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ABSTRACT 
 
The purpose of this research was to identify the effect of poor adherence to treatment 
of people living with HIV/AIDS. Due to the rise in HIV/AIDS related deaths this 
study tried to establish whether the support systems of People living with HIV/AIDS 
(PLWA) are in line with the actual needs of PLWA to adhere to effective treatment 
therapy. The researcher made use of a semi-structured interview to collect the 
required information.  
 
The findings of this study shows that certain obstacles prevent PLWA to adhere 
effectively to treatment and that these patients should be assisted in whatever way to 
overcome these obstacles to adhere effectively. Effective adherence to treatment 
therapy should further be enhanced through the implementation of good HIV/AIDS 
care practice that encourages patient involvement. 
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OPSOMMING 
 
Die studie het ten doel om vas te stel waarom persone met MIV/VIGS nie gunstig op 
terapie reageer nie, asook om die uitwerking van hierdie ongunstige reaksie te bepaal. 
In die lig van die styging in MIV/VIGS verwante sterftes poog hierdie studie verder 
om vas te stel of die huidige ondersteuningsisteme van persone met MIV/VIGS 
voldoen aan die eintlike behoeftes van sodanige persone om optimale reaksie op 
terapie te verseker. Inligting is met behulp van `n semi-gestruktureerde onderhoud 
verkry. 
Die studie het bevind dat sekere struikelblokke persone met MIV/VIGS verhoed om 
gunstig op terapie te reageer en dat sodanige persone ondersteun moet word om 
daardie struikelblokke te oorkom ten einde gunstige reaksie op behandeling te 
verseker. Hierdie ondersteuning behoort aangevul te word deur die instelling van 
gesonde MIV/VIGS ondersteuningspraktyke wat pasiënt-betrokkenheid insluit. 
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1. Working title: 
The effect of poor adherence to treatment of people living with HIV/AIDS. 
 
2. Background: 
Table 1: Global summary of the HIV/AIDS epidemic as per 2008 (UNAIDS 2009 
November): 
 Estimate Range 
People living with 
HIV/AIDS in 2008 
33.4 million 31.1 – 35.8 million 
Adults living with 
HIV/AIDS in 2008 
31.3 million 29.2 – 33.7 million 
Women living with 
HIV/AIDS in 2008 
15.7 million 14.2 – 17.2 million 
Children living with 
HIV/AIDS in 2008 
2.1 million 1.2 – 2.9 million 
People newly infected with 
HIV in 2008 
2.7 million 2.4 – 3.0 million 
Children newly infected 
with HIV in 2008 
0.43 million 0.24 – 0.61 million 
AIDS deaths in 2008 2.0 million 1.7 – 2.4 million 
Child AIDS deaths in 
2008 
0.28 million 0.15 – 0.41 million 
 
The following is of note: 
 More than 25 million people have died of AIDS since 1981. 
 There are over 14 million AIDS orphans in Africa. 
 At the end of 2008, women accounted for more than 50% of all adults living 
with HIV worldwide. 
 In developing and transitional countries, 9.5 million people are in immediate 
need of life saving AIDS drugs; of these, only 4 million (42%) are receiving 
the drugs. 
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Global trends of people living with HIV 
Figure 1 
 
The number of people living with HIV has risen from around 8 million in 1990 to 33 
million today, and is still growing. Around 67% of people living with HIV are in sub- 
Saharan Africa. 
 
Table 2: Regional statistic for HIV & AIDS, end of 2008 
Region 
Adults 
&children 
living with 
HIV/AIDS 
Adults & 
children 
newly infected 
Adult 
prevalence* 
Deaths of 
adults & 
children 
Sub – Saharan 
Africa 
22.4 million 1.9 million 5.2% 1.4 million 
North Africa & 
Middle East 
310, 000 35, 000 0.2% 20, 000 
South and 
South- East 
Asia 
3.8 million 280, 000 0.3% 270, 000 
East Asia 850, 000 75, 000 <0.1% 59, 000 
Oceania 59, 000 3900 0.3% 2, 000 
Latin America 2.0 million 170, 000 0.6% 77, 000 
0
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Caribbean 240, 000 20, 000 1.0% 12, 000 
Eastern Europe 
& Central Asia 
1.5 million 110, 000 0.7% 87, 000 
North America 1.4 million 55, 000 0.4% 25, 000 
Western & 
Central Europe 
850, 000 30, 000 0.3% 13, 000 
Global Total 33.4 million 2.7 million 0.8% 2.0 million 
*Proportion of adults aged 15 – 49 who were living with HIV/AIDS 
 
During 2008 more than two and a half million adults and children became infected 
with HIV (Human Immunodeficiency Virus), the virus that causes AIDS. By the end 
of the year, an estimated 33.4 million people worldwide were living with HIV/AIDS. 
The year also saw two million deaths from AIDS, despite recent improvements in 
access to antiretroviral treatment. 
 
It should be noted that adults are defined as men and women aged 15 or above, unless 
specified otherwise. Children orphaned by AIDS are defined as people aged under 18 
who are alive and have lost one or both parents to AIDS. Statistics utilized are global 
best estimates. 
 
Sandstrom et al. (2003) found in their research that HIV/AIDS is the fourth most 
common cause of death in the world. 
 
When analysing HIV/AIDS, significant data challenges are being identified. 
HIV/AIDS is a disease that remains at large misunderstood and it is also marked by 
significant social stigma. To be HIV-positive marginalises individuals from society, 
and bring shame and disrepute on their families. This leads to denial that is a common 
response and which in turn affects the identification and assessing of infection rates. 
 
Ever since the first report about HIV/AIDS infection in the early 1980s, the spread of 
the HIV/AIDS epidemic has been an ever-present feature of world news.  
This brings us to the question of what is HIV/AIDS about. 
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HIV/AIDS is an illness caused by a virus called the Human Immunodeficiency Virus 
(HIV) and it affects the human immune system by infecting the CD4+ cells, designed 
to combat infections. Once people are infected with HIV, they become prone to 
opportunistic infections. Tuberculosis is the most prominent infection. AIDS is 
diagnosed when a person diagnosed with HIV either becomes ill as a result of these 
infections, or when the number of CD4+ cells falls below a certain level.  
 
Perelson et al. (1996) found that the HIV virus replicates at a high rate in untreated 
patients and when replication occurs during treatment, it leads to the development of 
genetic variation, which in turn leads to the emergence of variants that might be 
resistant to antiretroviral treatment (Coffin 1995).Germs/diseases spread and if the 
germs in the body have become resistant and spread to another person, they too will 
become ill.  
  
Now what is resistance?  
Resistance implies that the germs get used to the drugs and that it will then no longer 
be able to successfully fight the germs. The person will then become more ill, stay ill 
or even die.  
 
The HIV virus easily becomes resistant to drugs and as such should People living with 
HIV/AIDS (PLWA) take their medication exactly as they are told. According to 
Bedell et al. (2000) only one-third of PLWA drink their medication as prescribed. 
Lerner, Gulick, Dubler (1998) found that although PLWA fully comprehend the 
consequences of non-adherence to medications, adherence rates are still suboptimal. 
When PLWA do not take their medication as the doctor prescribes, it is called non- 
adherence.  
 
Non-adherence is dangerous and a risk to one’s health. Non-adherence is normally 
caused by;  
 People who don’t take their medication three times per day as prescribed and 
at other times forget to take it.  
 Sometimes people stop taking their medication as it leads to dizziness or 
nausea. 
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 Side-effects also do play a part in PLWA decision to stop taking their 
medication.  
 People sometimes stop taking their medication when they feel better. 
 People sometimes stop using the medication on the advice of friends who tell 
them that it is bad for their health.  
 Sometimes they share their medication with others. 
 
If people stop taking their medication they will become ill again and when they 
resume taking it the HIV virus will be more difficult to fight. The medication will not 
help them any more. 
 
Antiretroviral adherence is the second strongest predictor of progression to AIDS and 
death, after CD4 count (Bangsberg et al. 2001). Adherence is defined by the World 
Health Organization (WHO) as; “the extent to which a person’s behaviour – taking 
medication, following a diet, and/or executing lifestyle changes, corresponds with 
agreed recommendations from a health care provider” (WHO 2003). 
 
While the disease is currently incurable, existing anti-retroviral therapy (ART) acts to 
inhibit opportunistic infections, and the onset of AIDS. The providing of antiretroviral 
therapy ensures a whole new social and economic context for people living with HIV 
since it allows for a productive life, averts premature death and prevents opportunistic 
infections (UNAIDS et al. 2000). 
 
3. Research question: 
Why do People that Live with HIV/AIDS (PLWA) not adhere to effective treatment 
therapy on HIV/AIDS and what can be done to discourage poor adherence? 
 
Knowledge gap: 
We do not know what PLWAs needs are regarding support use or the support 
services available to them. If this can be ascertained, the support services could 
be streamlined to meet the needs of the PLWA and so contribute to decreasing 
the numbers of PLWA who do not adhere to treatment therapy. 
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4. Significance of study: 
This study will take place in the area of the Langeberg Municipality to establish 
whether the support systems of PLWA in this area are in line with the actual needs of 
PLWA to adhere to treatment therapy in order to identify shortcomings in the support 
systems. 
 
5. Literature review: 
The treatment of HIV/AIDS is for life and as such is the usage of HIV/AIDS 
medication a lifelong commitment. The rapid replication and mutation rate of HIV in 
this area (Langeberg Municipality) necessitates the need for this study. PLWA often 
stop taking their medication when they are feeling better and this kind of behaviour 
usually leads to non-adherence because they don’t take their medication as medically 
prescribed.  
 
The primary reason for not achieving the full health benefits medication can provide 
can be addressed to non-adherence. According to Yach in WHO (2003) poor 
adherence causes medical and psychosocial complications of disease, reduces 
patients’ quality of life, increases the likelihood of development of drug resistance 
and wastes health care resources. These direct consequences, taken together impair 
the ability of health care systems around the world to achieve population health goals. 
 
Sabatè stated in WHO (2003) that better adherence will not threaten health care 
budgets but that adherence to those medication already prescribed will lead to a 
significant decrease in the overall health budget. According to him this is due to the 
reduction in the need for more costly interventions, such as frequent and longer 
hospitalizations, unnecessary use of emergency room and highly expensive intensive 
care services. The rational use of medication means good prescribing and full 
adherence to the prescriptions.  
 
a). Types of non-adherence: 
Non-adherence can take many different forms (Miller 1997). The patient may either 
fail to fill the prescription or time the medication incorrectly. Sometimes patients take 
the wrong dose because they misunderstood or forgot the health professional’s 
instructions. Patients also tend to forget a dose completely or they terminate the 
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medication prematurely. Side-effects, toxicity and personal beliefs in many occasions 
lead to a self-adjustment in regimen. 
  
b). Challenges in assessing adherence 
Gao and Nau (2000) has found in their research that it is easy to miss adherence 
problems because patients tend to exaggerate their self-reports in a desire to please the 
provider and avoid criticism. Others might have done away with their medication 
before a scheduled check to appear as if they have adhered (Rand et al. 1992). 
Inadequate adherence coupled with biased reporting is ubiquitous across medication. 
On the other hand it appears as if patients who report problems with adherence do not 
mislead their providers (Wagner & Rabkin 2000). 
 
Du Pasquier-Fediaevsky & Tubiana-Rufi (2002) found in their research that estimates 
of adherence made by health care providers are also usually over-optimistic. Health 
care providers are not very accurate in their prediction of which patients will adhere. 
Some do believe that factors such as lack of education and poverty are also good 
predictors of non-adherence. It is evident that predictors of adherence vary greatly 
across populations and settings and that factors associated with non-adherence differs 
across all studies (Chesney 2000). 
 
c). Predictors of adherence 
Four types of factors that have generally been found to predict problems with 
adherence to medication are: Regimen characteristics, various patient factors, the 
relationship between provider and patient and the system of care.  
 
i). Regimen-related factors 
a). Complexity of regimen.  
Chesney, Morin & Sherr (2000) has found that adherence to HIV medications 
is an extremely complicated process and that effective drug therapy includes 
both the drugs themselves as well as adjustments to daily life such as 
requirements or restrictions on food intake and other activities. These 
adjustments together with problems of toxicity and side-effects can play a 
major role in an individual’s willingness and ability to adhere to the therapy 
(Bartlett et al. 2000). 
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Despite the fact that the effect of pill burden is closely associated with disease 
stage many health professionals believe that pill burden strongly influences 
adherence. Gao et al. (2000) found in their research that symptomatic 
individuals risk for complications of non-adherence to medication is higher 
than asymptomatic patients. 
 
It appears that dosing schedules and food restrictions or requirements have a 
more permeable influence on adherence than pill burden. It appears that once-
daily or twice-daily doses are preferred as found by Eldred et al. (1998) who 
reported that patients on twice-daily doses or less reported better adherence 
(>80%). This was confirmed by Paterson et al. (2000) who also found that 
patients with a twice-daily dose adhered better than patients with a three-
times-daily dose.  
 
Wenger et al. (1999) came to the conclusion that the “fit” of the regimen to an 
individual’s lifestyle and schedule, as well as the individual’s attitude towards 
treatment are better predictors of adherence than dosing schedule.  
 
Halkitis P et al. (2003) found in their research that regimens that involve close 
monitoring; lifestyle alterations together with side-effects may not only 
frustrates patients but may lead to treatment fatigue and noncompliance. They 
concluded that regimens requiring fewer changes in lifestyle patterns have a 
positive influence on adherence to medication. Patients with strong biases 
against many pills and frequent dosing will benefit by reducing the number of 
pills and frequency of therapy, and minimizing drug interactions and side-
effects. Stone et al. (1998) found that adherence improved by simplified 
regimens that require fewer pills and lower dose frequencies. Before any 
regimens are chosen it is important that the patient’s eating habits should be 
reviewed and the specific food requirements discussed so that the patient 
understands what is required of him/her. Patients suffering from wasting will 
find regimens requiring an empty stomach several times per day difficult just 
as patients with fat aversion regimens requiring a high fat intake. 
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b). Side-effects.  
Side-effects have also been consistently associated with decreased adherence.  
Stone (2001) found in his research that patients who experience more than two 
aversive reactions are less likely to continue their treatment therapy. 
Patients quickly stop therapy or want to change their medication if they 
experience side-effects. Side-effects are responsible for more regimen changes 
than does treatment failure. D’Arminio et al. (2000) report in their research 
that more than 25% of treatment-naive patients do end their treatment within 
the first year of initiation of treatment due to toxicity and other side-effects.  
D’Arminio et al. (2000) found that fatigue, diarrhoea, nausea and stomach 
pain cause the most distress. Kasper et al. (2000) found that lipodystrophy 
plays a major role in the 37% of their respondents that either stopped or 
changed their medications.  
 
ii). Patient-related factors  
The critical link between a prescribed regimen and treatment outcome is a patient’s 
behaviour and the most effective regimen will fail if the patient does not take the 
medication as prescribed or refuses to take it. Chesney (2000) concluded that 
consequently, all things being equal, the most important factors influencing adherence 
are patient-related. 
 
a). Psychosocial issues.  
Chesney (1997) found that life stress interferes with proper dosing of protease 
medication regimens and that such stress is often experienced by individuals 
of low socioeconomic status. Although studies of most demographic 
characteristics of patients have generally failed to establish consistent links 
with adherence to medication, research by Stone (2001) have described 
several variables that have a possible association. Adherence is apparently 
most difficult for patients with lower levels of education and literacy. 
 
Halkitis, P. et al. (2003) have found that women have cited the stress of 
childcare as a reason for missing doses. Alcohol abuse, intravenous drugs and 
depressive symptoms also plays a part in poor adherence to medication. 
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Mocroft et al. (1999) demonstrated that although intravenous drug abusers 
were less likely to start with antiretroviral therapy, the response of those who 
did was similar to that of other exposed groups. 
 
Psychological distress affect adherence. The most significant predictors of 
adherence are depression, stress, and the manner in which individuals manage 
stress. Hopelessness and negative feelings can reduce the motivation to care 
for oneself can be minimized by hopelessness and negative feelings and it may 
also influence a patient’s ability to follow instructions.  
 
Social support also affects adherence behaviour. Paterson et al. (2000) found 
that patients with support from friends and families tend to adhere to HAART 
better than those without these supports. They also concurs that in addition to 
the support of a good relationship between providers and patients, adherence 
can be improved by providing a telephone-counseling line where PLWA can 
left messages for nurses, and enlisting the support of pharmacists (Paterson et 
al. 1999). It is important for patients to involve family and friends in their 
care, and to follow up on referrals to support groups, peer-counseling and 
community-based organizations. 
 
b). Patient-belief system.  
The knowledge and beliefs about disease and medication can play a major role 
in adherence. Chesney et al. (2000) found in their research that a patient’s 
understanding of the relationship between adherence and viral load and 
between viral load and disease progression plays a vital role in good adherence 
behaviour. Wenger et al. (1999) found that patients who believed antiretroviral 
medication to be effective adhere better. 
  
Adherence behaviour can also be affected by confusion and difficulty in 
understanding instructions especially requirements and/or restrictions on the 
intake of food and water and temporal sequences of dosing. Patients may get 
confused because of the complexity of a regimen, and/or from poor 
instructions from the health care provider.  
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Chesney et al. (2000) found in their research that the most commonly cited 
reason for non-adherence is forgetfulness; for example, they reported that 66% 
of their respondents gave this as the main reason for their non-adherence.  
 
iii). Patient–provider relationship. 
A relationship between the patient and health care provider that is meaningful and 
supportive can help patients to overcome barriers to adherence. According to Chesney 
(2000) factors like perceptions of provider competence, quality and clarity of 
communication, compassion, involving the patient as an active participant in 
treatment decisions and convenience of the regimen are factors that strengthen the 
relationship between patient and provider. Patients become frustrated with health care 
providers when over misunderstandings when side-effects go unmanaged and 
especially when treatment becomes complex and the patient is blamed for being a 
“bad patient”. These frustrations may lead to poor adherence. 
 
6. Aim and Objectives 
 
Aim: 
Due to the rise in HIV/AIDS statistics the aim of this study is to establish whether the 
support systems of PLWA are in line with the actual needs of PLWA to adhere to 
effective treatment therapy. 
 
Objectives: 
The objectives of this study are; 
 Levels of motivation and factors influencing PLWA to adhere to ARV 
treatment therapy. 
 To establish why PLWA are using support system(s) in helping them to adhere 
to treatment therapy. 
 PLWA requirements to enhance adherence to treatment therapy. 
 To provide health care workers with possible guidelines to strategize 
effectively to help PLWA adhering to treatment therapy. 
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7. Research design and methods 
Research design: 
This study will take on the form of a qualitative study using a semi-structured 
interview. 
 
Criteria for the target group: 
 Age group 20 – 40  
 Dependence on care givers for support and encouragement to take their 
medication 
 Functionally Literate  
 People living with Aids  
 
Respondents who took part in this study: 
 
Table 3: Respondents by age and gender – number and (%) 
 Male Female Total 
20-29 years 16 (32.0%) 16 (32.0%) 32 (64.0%) 
30-40 years 10 (20.0%) 8 (16.0%) 18 (36.0%) 
Total 26 (52.0%) 24 (48.0%) 50 (100%) 
 
Method of data collection: 
The measuring instrument was a self constructed semi-structured interview 
designed to establish whether the support systems of PLWA at the HIV/AIDS Clinic 
at Robertson Hospital are in line with their actual needs to adhere to treatment 
therapy. The clinic is a few metres away from the hospital. The respondents that met 
the study criteria were chosen with the help of the head of the clinic and after a review 
of the respondent’s hospital records. The respondents completed an anonymous 
questionnaire that was handed out to them by the head of the clinic. The answered 
questionnaires were collected by the researcher after the respondents had placed these 
in a sealed box. The response rate was found to be 100%. 
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8. Data analysis and discussion 
 
8.1 Levels of motivation and factors influencing PLWA to adhere to ARV 
treatment therapy 
 
Data clearly shows that before starting with treatment 35(70.0%) of the respondents 
were very motivated to undergo treatment while 10(20.0%) were less motivated and 
5(10.0%) were not motivated at all. This figure changed dramatically after the 
commencement of therapy with 94.0% of the respondents being motivated while 
6.0% of the respondents remained unmotivated to adhere to treatment. This represents 
a significant increase of 24.0% in the respondents that are motivated in taking the 
medication. The reason for this change in motivation is due to the fact that according 
to them they feel better, healthier and stronger after taking the medication and that the 
problems which caused their non-adherence were looked after. The 6.0% who were 
less motivated felt that there was no change in their health and that they were still 
feeling the same as before taking the medication. This finding clearly shows that the 
level of a persons’ motivation plays an important part in treatment adherence and that 
improvement in health is an important factor increasing levels of adherence. It also 
confirms the findings of Wenger et al (1999) who found better adherence in patients 
who believed antiretrovirals to be effective. 
 
Motivation of respondents before starting with treatment 
 
Table 4: Levels of motivation by gender – number and (%) 
 
 Women 
 
Men Total 
Very Motivated 20(40.0%) 15(30.0%) 35 (70.0%) 
Less Motivated 0(0%) 10 (20.0%) 10 (20.0%) 
Not Motivated 4(8.0%) 
 
1(2.0)% 5 (10.0%) 
Total 24 (48.0%) 26 (52.0%) 50 (100%) 
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Table 5: Levels of motivation by gender and age – number and (%) 
 
Age & Sex 
Very 
Motivated Less Motivated Not Motivated 
Total 
Males (20-29) 11 (22.0%) 5 (10.0%) 0(0%) 16 (32.0%) 
Males (30-40) 4 (8.0%) 5 (10.0%) 1 (2.0%) 10 (20.0%) 
Females (20-
29) 15 (30.0%) 0(0%) 1 (2.0%) 
 
16 (32.0%) 
Females (30-
40) 5 (10.0%) 0(0%) 3 (6.0%) 
 
8 (16.0%) 
Total 35(70.0%) 10(20.0%) 5(10.0%) 50 (100%) 
 
This finding shows the following: 
 Out of the 35(70.0%) highly motivated respondents 20(40.0%) were women 
and 15(30.0%) men. At the beginning women were more motivated than men 
to undergo treatment. The reason for this difference in motivation may be 
derived from the fact that women have families and have dependents. Right at 
the beginning men were less motivated than women due to the fact that they 
reported feeling strong and healthy and see treatment as a waste of time.   
 From the very motivated males 11(22.0%) were from the age group 20-29 
while 4(8.0%) were from the age group 30-40. The same scenario was found 
with the very motivated females where 15(30.0%) were from the age group 
20-29 and 5(10.0%) from the age group 30-40. This shows that the younger 
respondents were found more eager to undergo treatment than the older 
respondents.  
 The 10(20.0%) less motivated respondents were all men while the 5(10.0%) 
not motivated respondents consists of 1(2.0%) male and 4(8.0%) women. 
 From the 4(8.0%) not motivate women only 1(2.0%) were from the age group 
20-29 while the other 3(6.0%) were from the age group 30-40. This shows 
that the younger women were more motivated than the older women 
respondents to start with ARVs. One of the reasons for these findings may be 
that the younger respondents realised that their whole lives still lay ahead of 
them and that they will be able to lead a normal life with HIV/AIDS.  
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Motivation of respondents after starting with treatment: 
 
Table 6: Levels of motivation by gender – number and (%) 
 
  Women Men 
 
Very Motivated 47(94.0%) 27(54.0%) 20(40.0%) 
Less Motivated 0(0%) 0(0%) 0(0%) 
Not Motivated 3(6.0%) 2(4.0%) 1(2.0%) 
 
 
Table 7: Levels of motivation by gender and age – number and (%) 
 
 Age & Sex Very Motivated Less Motivated Not Motivated 
Males (20-
29) 16(32.0%) 0(0%) 0(0%) 
Males (30-
40) 9 (18.0%) 0(0%) 1 (2.0%) 
Females 
(20-29) 16 (32.0%) 0(0%) 0(0%) 
Females 
(30-40) 
6 (12.0%) 0(0%) 2 (4.0%) 
Total 50 47(94.0%) 0(0%) 3(6.0%) 
 
Table 8: Comparison between before and after starting with treatment therapy: 
 
 Before After 
 
Very Motivated  35(70.0%) 47(94.0%) 
Less Motivated 10(20.0%)                   0(0%) 
Not Motivated 5(10.0%) 3(6.0%) 
Total 50(100%) 50(100%) 
 
The abovementioned table shows an increase of 12(24.0%) respondents which 
boosted the very motivated respondents to a total of 47(94.0%), Out of the increase of 
12(24.0%) respondents 7(14.0%) were women and 5(10.0%) were men. The reason 
for this change in motivation can be found in the fact that the respondents felt better 
and healthier after taking the medication as well as the fact that others – doctors, 
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nurses, counsellors and family members - were also interested in their wellbeing. 
They also reported high levels of lifestyle change by reducing alcohol intake and 
adhering with the scheduled intake of the prescribed medication. This data clearly 
shows that some time after taking the medication the older men respondents 9(18.0%) 
were more motivated to go on with the treatment therapy than the women respondents 
of the same age 6(12.0%). The male and female respondents in the age group 20 – 29 
were evenly motivated to continue with the treatment therapy - total of 16(32.0%). 
 
8.2 Why PLWA are using support systems in helping them to adhere to 
treatment therapy 
The reason for the rise in the adherence percentages can clearly be related to the 
human factor, the respondents were encouraged by care-givers to overcome the 
problems that were causing non-adherence. Out of the 50 respondents, 26(52.0%) 
respondents stated that they experienced problems right at the start when it comes to 
taking ARVs while 24(48.0%) respondents did not experience any problems.  
The 26(52.0%) respondents express the following main reason for not taking the 
prescribed medication: 
 A shortage of money to buy food as some medication require a full stomach 
4(8.0%),  
 A shortage money to pay for their taxi-fare since the clinic is not in walking 
distance of their homes 3(6.0%)  
 Forgetfulness 2(4.0%).  
 Side-effects 3(6.0%)  
 Stigmatisation 3(6.0%) 
 Change in lifestyle 3(6.0%) 
 Alcohol abuse 3(6.0%) 
 Hopelessness and negativity 2(4.0%) 
 The belief that they will eventually die of HIV/AIDS and that the medication 
only give them time to get their personal stuff in order so that their kids will 
be looked after when they eventually dies  1(2.0%) 
 Hopelessness and negative feelings that reduce the motivation to care for one 
and which also influences the patient’s ability to follow complex instructions 
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2(4.0%).These findings corresponds with studies by Chesney et al. (2000) 
which demonstrated a relationship between adherence and depression.  
 
This study clearly shows that side-effects are also responsible for the drop in the 
adherence percentage of males and female age 30 – 40. In this case 2(4.0%) of the 
women respondents age 30 – 40 years failed to take a dose  during the last month due 
to side-effects causes by the medication. This finding corresponds with the findings of 
Chesney (2000) who found in his research that adherence is reduced by medications 
that produce side-effects. This finding also corresponds with the findings of Kasper et 
al. who found that (37.0%) respondents either stopped or changed their medication 
due to side-effects. From those respondents who were adherent (57.0%) stated serious 
consideration of discontinuation of the medication while some (46.0%) acknowledge 
that they would stop if the symptoms worsened. It also corresponds with the findings 
of Chesney (2000) who found better adherence in patients with simplified regimens 
that require fewer pills and lower dose frequencies.  
 
In terms of breakdown of results by age, older respondents 17(34.0%) experience 
more problems than the younger respondents in adhering to treatment 9(18.0%).  
Problems that elderly respondents experience are: 
 A shortage of money to buy food as some medication require a full stomach 
5(29.5%) 
 A shortage money to pay for their taxi-fare since the clinic is not in walking 
distance of their homes 3(17.6%) 
 Forgetfulness 3(17.6%) 
 Side-effects 3(17.6%) 
 Believe they will eventually die 1(5.9%) 
 Hopelessness and negativity 2(11.8%) 
 
The greatest problems of younger respondents are:  
 Stigmatisation 3(33.3%) and  
 Change in lifestyle 3(33.3%). 
 Alcohol abuse 3(33.3%) 
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Table 9: Factors enhancing non adherence for elderly respondents – number and 
(%) 
 
 Males 
(20 – 29) 
Males 
(30 – 40) 
Female 
(20 – 29) 
Females 
(30 – 40yr.) 
Food 
Shortage 
0(0%) 2(11.8%) 0(0%) 3(17.6%) 
Transport Fee 0(0%) 1(5.9%) 0(0%) 2(11.8%) 
Forgetfulness 0(0%) 2(11.8%) 0(0%) 0(0%) 
Side-effects 0(0%) 2(11.8%) 0(0%)       2(11.8)% 
Believe they’ll 
eventually die 
0(0%) 1(5.9%) 0(0%) 0(0%) 
Hopelessness 
& negativity 
0(0%) 2(11.8 %) 0(0%) 0(0%) 
 
 
Table 10: Factors enhancing non adherence for younger respondents – number  
and (%): 
 
 Males 
(20 – 29) 
Males 
(30 – 40) 
Female 
(20 – 29) 
Females 
(30 – 40yr.) 
Stigmatisation 1(11.1%) 0(0%) 2(22.2%) 0(0%) 
Lifestyle 
change 
2(22.2%) 0(0%) 1(11.1%) 0(0%) 
Alcohol abuse 2(22.2%) 0(0%) 1(11.1%) 0(0%) 
 
 
8.3 PLWA requirements to enhance adherence  to treatment therapy 
Chesney et al. (2000) found that a patient’s knowledge and beliefs about disease and 
medication can influence adherence. Here the role as well as the attitude of the person 
who gave the information when starting the first treatment whether it is the doctor,  
nurse or counsellor is of great importance. 
 24 
In the case of information supplied before starting the treatment the following 
percentages were found. 
 30% by the counsellor 
 50% by the sister 
 20% by the doctor  
 This clearly shows that more respondents get their information from the sister mainly        
because she tested them for HIV/AIDS, followed by the counsellor and then the 
doctor. 
 
Table 11: Information suppliers 
 
Counsellor Doctor Sister (Nurse) 
15(30.0%) 10(20.0%) 25(50.0%) 
 
This study also shows that:  
 30(60.0%) of the respondents prefer to get their information from the person 
who initially  supplied them with information be it either the counsellor, 
doctor or nurse because he/she:  
 Had the right attitude 
 Understands them and their fears   
 Has patience and  
 shows a caring attitude while 
 20(40.0%) of the respondents prefer to get their information from 
another source because of experiencing a harsh and uncaring attitude whether 
it be the counsellor, doctor or nurse  
           
This study shows that: 
 5(10.0%) of the respondents makes a habit of not adhering to treatment because 
they don’t want to take the medication.  
 26(52.0%) of the respondents sometimes forgot to take their medication due to 
the following reasons: 
 A shortage of money to buy food as the intake of some medication 
requires a full stomach -5(10.0%) – young and old men and women. 
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 A shortage money to pay for their taxi-fare since the clinic is not in 
walking distance of their homes -3(6.0%) mainly older women 
 Forgetfulness -3(6.0%) older men and women. 
 Side-effects -3(6.0%) older men and women 
 Stigmatisation -3(6.0% ) younger men and women 
 Change in lifestyle -3(6.0%) young men and women 
 Alcohol abuse -3(6.0%) mainly young men 
 The belief that they will eventually die of HIV/AIDS and that the 
medication only give them time to get their personal stuff in order so 
that their kids will be looked after when they eventually dies -1(2.0%) 
mainly older men. 
 Hopelessness and negative feelings that reduce the motivation to care 
for one and which also influences the patient’s ability to follow 
complex instructions 2(4.0%) mainly older men. 
 19(38.0%) of the respondents make sure that they remember to take their 
medication or ask someone to remind them to take their medication. 
 
During this study 43(86.0%) of the respondents genuinely believe that the treatment 
as well as seeing to the abovementioned “problems” will prevent them from becoming 
ill  rapidly as a result of HIV/AIDS while 7(14.0%) believes otherwise. Of the 
43(86.0%), 30(60.0%) are women and 13(26.0%) are men. More young men and 
women believe that the treatment will work because they feel healthier and better 
after taking the medication. The older men on the other hand feel that the treatment 
will not  work because they believe that they will eventually die of HIV/AIDS and 
that the medication only give them time to get their personal affairs in order so that 
their kids will be looked after when they eventually dies. 
 
This clearly shows that the person who supplies the patient with information right at 
the start needs to play a caring and understanding role in the patient’s life. He should 
be able to understand his patient’s needs and shortcomings and encourage him or her 
to adhere no matter the cost. The caregiver should also be in close contact with the 
patient’s family to help identify possible problems that would handicap the patient in 
trying to adhere to therapy and to help the patient in finding possible solutions. 
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8.4 Guidelines to strategize to help PLWA adhering to treatment therapy 
Shortcomings identified through this study in the support systems indicate that a 
multifaceted approach to improve adherence is the most likely to be beneficial. This 
study further points out that patients must be given a chance to be actively involved in 
decisions that concerns their health This involvement by the patient should be 
combined with appropriate support, multidimensional educational programmes that 
teach behavioural skills to enhance adherence, together with the tailoring of the 
regimen to fit the patient. 
 
Together with the abovementioned, the role of the person who gives the information 
in the first instance – nurse, doctor or counsellor -  to the patient is of utmost 
importance. He or she should show a caring attitude towards the patient as well as a 
genuine interest in the wellbeing of the patient. Spot checks must be the order of the 
day to make sure that the patient takes his medication as prescribed irrespective of the 
factors that discourages them not to take their medication.  
 
It would also be best for the patient-provider relationship if the health practitioner 
works together with the patient to select a regimen that will fit his or her lifestyle. 
Where it seems that more than one regimen may be appropriate, providers may want 
to discuss the regimen, the quantity of pills, the dosing schedule, instructions and 
potential side effects with the patient. Patients should therefore be helped and 
strategies provided to help them manage any side-effects that may occur because side-
effects as seen above are usually associated with non-adherence. It is essential for an 
effective patient-provider relationship that the providers and their team members 
should remain in close contact with the patient during early treatment with a new 
regimen to allow for the timely identification and management of all side-effects and 
toxicities. Such close contact can be advantageous in reinforcing adherence 
behaviour. It is of great importance that health care providers and their teams should 
address the patient-related factors and psychosocial issues associated with non-
adherence as soon as possible after a regimen is decided upon. 
 
This handling of the situation will lead to a more appropriate and collaborative 
relationship between the practitioner and the patient. This action will in all likelihood 
enhance adherence. 
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Adherence can also be greatly enhanced by the support of family members and 
“significant others”, or employing “treatment buddies” to administer medications. 
Patients must be encouraged to get such help from their families and friends and on 
the other hand families and friends must also be encouraged to get involved. 
 
Last but not least, regular and positive feedback is regarded as one of the powerful 
reinforcers of adherence behaviour.  To enhance good adherence behaviour feedback 
should be conducted soon after the initiation of treatment to show the extent to which 
it has been effective. Communication and the managing of it play a vital role in 
getting PLWA to adhere. Patients should always be encouraged to never give up 
hope.  
 
 9. Conclusion 
This study shows that adherence is clearly the important factor in managing 
HIV/AIDS and how important it is that the patient should be assisted in whatever way 
to overcome the obstacles that prevent him/her from adhering to ARV treatment. The 
patient should be clear about the importance of adhering as well as the seriousness of 
the consequences when not adhering.  
 
To fight effectively against this disease it is necessary to implement projects of good 
HIV/AIDS care practice that encourages patient-involvement.  
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